Business Context and Reporting Period
Company: Neuphoria Therapeutics Inc. (NEUP)
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2025
Event: Adoption of a limited-duration stockholder rights plan (Poison Pill) and declaration of a dividend of rights to purchase Series A Preferred Stock.
Key Financial Metrics
This filing is a current report regarding a corporate governance action and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Corporate Actions
- Trigger for Action: The Board adopted the Rights Plan in response to significant and rapid accumulation of Company Common Stock by certain investors. Specifically, an individual investor informed the Company of holding more than 20% of outstanding common stock as of October 23, 2025.
- Dividend Declaration: On October 25, 2025, the Board declared a dividend of one Right to purchase 1/1,000th of a Series A Preferred Share for each outstanding share of Common Stock.
- Record Date: October 27, 2025.
- Expiration: Rights expire on October 27, 2026, unless earlier redeemed or exchanged.
- Grandfathering: Stockholders with beneficial ownership above the 15% threshold as of the first public announcement (October 27, 2025) are grandfathered at current levels but cannot increase ownership without triggering the Rights.
Terms of the Rights Plan and Outlook
Key Terms
- Trigger Threshold: Beneficial ownership of 15% or more of outstanding Common Stock by a person or group (Acquiring Person).
- Exercise Price: $85.00 per Right to purchase 1/1,000th of a Preferred Share.
- Flip-In Feature: If triggered, holders (excluding the Acquiring Person) may purchase Common Stock with a market value of twice the Exercise Price.
- Flip-Over Feature: If the Company is acquired after the Distribution Date, holders may purchase shares of the acquiring entity with a market value of twice the Exercise Price.
- Redemption: The Board may redeem Rights for $0.001 per Right at any time prior to an Acquiring Person emerging or the Final Expiration Date.
- Preferred Share Rights: Each Preferred Share carries voting power equal to 1,000 Common Shares and preferential liquidation rights.
Management Commentary and Strategic Intent
The Board states the plan is intended to protect stockholder investment during a period where shares may not reflect intrinsic value and to provide time for informed judgment. The plan does not prevent the Board from engaging with parties or accepting acquisition proposals if deemed in the best interests of the Company. On October 27, 2025, the Company also announced it is evaluating strategic alternatives.
Investor Verification Checklist
- Verify the current beneficial ownership percentage of the individual investor holding over 20% of the stock to confirm if they are grandfathered or if the Rights have been triggered.
- Review the full text of the Rights Agreement (Exhibit 4.1) for specific definitions of "Acquiring Person" and exceptions for derivative positions.
- Monitor for any press releases regarding the evaluation of strategic alternatives mentioned in Item 8.01.
- Check the Company's capitalization table to understand the potential dilution impact if the "Flip-In" or "Flip-Over" provisions are activated.
- Confirm the status of the Series A Preferred Stock designation filed with the Delaware Secretary of State (Exhibit 3.1).